Skip to main content
SpringerLink
Log in

Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children

  • Original Article
  • Published:
Pediatric Radiology Aims and scope Submit manuscript

Abstract

Background

Ferumoxytol is an ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle agent used to treat iron deficiency anemia in adults with chronic kidney disease.

Objective

We aim to determine the feasibility of using ferumoxytol for clinical pediatric cardiac and vascular imaging.

Material and methods

We retrospectively identified 23 consecutive children who underwent MRI with ferumoxytol (11 males; mean age: 7.4 years, range: 3 days–18 years), yielding 12 abdominal MR angiography and 15 cardiac MRI studies. Medical records were reviewed for the clinical indication, ferumoxytol dose, injection rate, sedation and any complication. A two-reader consensus scored the images on a five-point scale for overall image quality and delineation of various anatomical structures. Signal-to-background ratios for abdominal aorta and inferior vena cava for abdominal cases and blood pool-myocardium contrast ratios for cardiac cases were calculated. The confidence intervals for obtaining a score of three or above for each image parameter were calculated by using adjusted Wald method.

Results

For abdominal MR angiography, average scores for overall image quality, as well as delineation of the hepatic artery, superior mesenteric artery, renal artery and veins were 4.5, 4.3, 4.3, 3.7 and 4.7, respectively. For cardiac exams, the average scores for overall image quality, systemic arteries, pulmonary arteries, pulmonary veins, valves and ventricles were 4.4, 4.6, 4.1, 4.8, 4.1 and 4.7, respectively. For all parameters, the lower bound for the proportion of cases to have a score of 3 or above was 65%. Signal-to-background ratios for aorta and abdominal veins averaged 86 +/− 74 and 86 +/− 77 for full-dose images, and 23 and 18 for half-dose images, respectively. Mean blood pool to myocardium contrast ratio was 3:3.

Conclusion

Ferumoxytol can provide excellent image quality for pediatric body MR angiography/MR venography at a dose of 1.5 or 3 mg Fe/kg. Further investigation should be directed toward understanding the lowest dose that can be administered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Prince MR, Zhang HL, Chabra SG et al (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240

    CAS  PubMed  Google Scholar 

  2. Li W, Tutton S, Vu AT et al (2005) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 21:46–52

    Article  PubMed  Google Scholar 

  3. Bremerich J, Bilecen D, Reimer P (2007) MR angiography with blood pool contrast agents. Eur Radiol 17:3017–3024

    Article  PubMed  Google Scholar 

  4. Bashir MR, Mody R, Neville A et al (2014) Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. J Magn Reson Imaging 40:113–118

    Article  PubMed  Google Scholar 

  5. Sigovan M, Gasper W, Alley HF et al (2012) USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 265:584–590

    Article  PubMed Central  PubMed  Google Scholar 

  6. Ersoy H, Jacobs P, Kent CK et al (2004) Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol 182:1181–1186

    Article  PubMed  Google Scholar 

  7. Gahramanov S, Muldoon LL, Varallyay CG et al (2013) Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 266:842–852

    Article  PubMed Central  PubMed  Google Scholar 

  8. Hamilton BE, Nesbit GM, Dosa E et al (2011) Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 197:981–988

    Article  PubMed Central  PubMed  Google Scholar 

  9. Li W, Salanitri J, Tutton S et al (2007) Lower extremity deep venous thrombosis: evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism–preliminary experience. Radiology 242:873–881

    Article  PubMed  Google Scholar 

  10. McCullough BJ, Kolokythas O, Maki JH et al (2013) Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 37:1476–1479

    Article  PubMed  Google Scholar 

  11. Stabi KL, Bendz LM (2011) Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 45:1571–1575

    Article  CAS  PubMed  Google Scholar 

  12. Thompson EM, Guillaume DJ, Dosa E et al (2012) Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurol 109:105–114

    Google Scholar 

  13. Schiller B, Bhat P, Sharma A (2013) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83

    Article  PubMed  Google Scholar 

  14. Schieda N (2013) Parenteral ferumoxtol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning. Insights Imaging 4:509–512

    Article  PubMed Central  PubMed  Google Scholar 

  15. Institute of Medicine, Food and Nutrition Board (2011) Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc : a report of the panel on micronutrients. National Academy Press, Washington, DC

    Google Scholar 

Download references

Acknowledgment

This work is supported by a grant from the National Institutes of Health (R01 EB009690 and P41 EB015891) and the Tashia and John Morgridge Faculty Scholar Fund.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Diagnostic and Therapeutic Radiology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Nichanan Ruangwattanapaisarn

  2. Department of Radiology, Stanford University, 725 Welch Road, Rm 1681, Stanford, CA, 94305, USA

    Nichanan Ruangwattanapaisarn, Albert Hsiao & Shreyas S. Vasanawala

Authors
  1. Nichanan Ruangwattanapaisarn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Albert Hsiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shreyas S. Vasanawala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shreyas S. Vasanawala.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruangwattanapaisarn, N., Hsiao, A. & Vasanawala, S.S. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol 45, 831–839 (2015). https://doi.org/10.1007/s00247-014-3226-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00247-014-3226-3

Keywords

Search

Navigation